In PC3 prostate cancer (PCa) models, MYC elevates glutaminolysis by indirectly enhancing translation of glutaminase 1 (GLS1), via inhibiting the GLS1 repressors, miR-23a/b [158]. The gene discussed is GLS; the disease is prostate carcinoma.